Advertisement vbandhakavi, Author at Pharmaceutical Business review - Page 58 of 72
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by vbandhakavi 

CRISPR, MaxCyte expand partnership into immuno-oncology

The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. CRISPR

Alexion wraps up $1.2bn acquisition of Syntimmune

The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with